Spruce Biosciences (SPRB)
NASDAQ:SPRB
Want to see SPRB full AI Analyst Report?
Top Page
Spruce Biosciences
(NASDAQ:SPRB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$50.00
▼(-28.88% Downside)
Action:ReiteratedDate:04/23/26
The score is held down primarily by weak financial performance (no recent revenue, ongoing losses, and continued cash burn) and a technically weak price trend below key moving averages. Corporate events provide a partial offset through improved funding and supportive pipeline/regulatory updates, while valuation support is limited due to losses and no indicated dividend yield.
Positive Factors
Disease-modifying clinical data (TA-ERT)
Robust multi-year data showing durable biomarker normalization and preserved cognitive/motor function supports first-in-class, disease-modifying positioning for MPS IIIB. If replicated in pivotal studies, this creates a sustainable clinical moat and durable commercial upside in an ultra-rare indication with no approved therapies.
Negative Factors
No product revenues and persistent losses
The firm lacks recurring product revenue and continues to post substantial operating losses, driving negative free cash flow. Over the medium term this necessitates capital markets access to fund operations, increasing dilution risk and making long-term viability contingent on successful approval or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Disease-modifying clinical data (TA-ERT)
Robust multi-year data showing durable biomarker normalization and preserved cognitive/motor function supports first-in-class, disease-modifying positioning for MPS IIIB. If replicated in pivotal studies, this creates a sustainable clinical moat and durable commercial upside in an ultra-rare indication with no approved therapies.
Read all positive factors
Spruce Biosciences (SPRB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$150.02M
Dividend YieldN/A
Average Volume (3M)988.68K
Price to Earnings (P/E)―
Beta (1Y)-10.43
Revenue Growth-100.00%
EPS Growth45.32%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.73
Shares Outstanding2,702,043
10 Day Avg. Volume2,922,716
30 Day Avg. Volume988,676
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.60K
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$198.25Price Target Upside182.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-36.72
Revenue Forecast (FY)N/A
Spruce Biosciences Business Overview & Revenue Model
Company Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and r...
How the Company Makes Money
As a clinical-stage biotechnology company, Spruce Biosciences has not had a stable, recurring revenue base from marketed products; its operations have primarily been funded through external financing rather than product revenue (e.g., raising capi...
Spruce Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 4.91M | 10.09M | 0.00 | 0.00 |
| Gross Profit | -21.00K | 4.91M | 10.09M | 0.00 | 0.00 |
| EBITDA | -36.51M | -52.68M | -47.37M | -45.69M | -41.88M |
| Net Income | -38.97M | -53.04M | -47.92M | -46.18M | -42.29M |
Balance Sheet | |||||
| Total Assets | 53.02M | 45.21M | 103.95M | 85.65M | 126.49M |
| Cash, Cash Equivalents and Short-Term Investments | 48.91M | 38.75M | 96.34M | 79.08M | 88.97M |
| Total Debt | 736.00K | 2.77M | 4.61M | 6.32M | 6.53M |
| Total Liabilities | 10.51M | 16.39M | 27.44M | 17.16M | 15.12M |
| Stockholders Equity | 42.52M | 28.82M | 76.51M | 68.49M | 111.37M |
Cash Flow | |||||
| Free Cash Flow | -33.33M | -55.96M | -33.28M | -41.69M | -35.97M |
| Operating Cash Flow | -33.33M | -55.96M | -33.27M | -41.68M | -35.88M |
| Investing Cash Flow | 0.00 | 0.00 | 55.78M | 23.69M | -79.17M |
| Financing Cash Flow | 43.48M | -1.62M | 49.14M | -241.00K | 643.00K |
Spruce Biosciences Technical Analysis
Positive
70.30
Price Trends
63.42
Positive
73.79
Negative
61.96
Positive
Market Momentum
1.32
Negative
57.06
Neutral
75.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SPRB, the sentiment is Positive. The current price of 70.3 is above the 20-day moving average (MA) of 65.30, above the 50-day MA of 63.42, and above the 200-day MA of 61.96, indicating a bullish trend. The MACD of 1.32 indicates Negative momentum. The RSI at 57.06 is Neutral, neither overbought nor oversold. The STOCH value of 75.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SPRB.
Spruce Biosciences Risk Analysis
Spruce Biosciences disclosed 76 risk factors in its most recent earnings report. Spruce Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Spruce Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $178.04M | -1.14 | -96.96% | ― | -50.12% | -368.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $136.62M | -0.86 | -1197.81% | ― | ― | 27.88% | |
50 Neutral | $68.31M | -2.21 | 240.83% | ― | -41.52% | 42.50% | |
45 Neutral | $150.02M | -1.71 | -203.99% | ― | -100.00% | 45.32% | |
45 Neutral | $66.33M | -0.74 | -33.97% | ― | ― | 47.28% | |
44 Neutral | $71.49M | -6.48 | 15.86% | ― | 9.69% | 98.38% |
* Healthcare Sector Average
SPRB
Spruce Biosciences
55.52
50.03
911.29%
IMUX
Immunic
10.03
-1.67
-14.27%
FBIO
Fortress Biotech
2.22
0.47
26.86%
CLNN
Clene
5.80
2.80
93.33%
DTIL
Precision BioSciences
6.90
1.18
20.63%
IMA
ImageneBio
5.93
-8.71
-59.49%
Spruce Biosciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Spruce Biosciences Prices Equity Offering to Raise Capital
Positive
Apr 22, 2026
On April 20, 2026, Spruce Biosciences entered into an underwriting agreement with a syndicate led by Leerink Partners, Guggenheim Securities and Oppenheimer to sell 1,150,000 shares of common stock at $50.00 per share and 50,000 pre-funded warrant...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline
Positive
Mar 20, 2026
On March 16, 2026, Spruce Biosciences agreed with Kaken Pharmaceutical to terminate their January 2023 collaboration covering tildacerfont for congenital adrenal hyperplasia in Japan, effective March 31, 2026, ending all licenses and rights and el...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Spruce Biosciences Updates ATM Agreement, Strengthens Leadership Team
Positive
Mar 9, 2026
On March 9, 2026, Spruce Biosciences entered a new open market sale agreement with Jefferies to allow at-the-market issuances of common stock under an existing shelf registration, replacing a prior 2022 sales agreement and providing additional fin...
Business Operations and StrategyProduct-Related Announcements
Spruce Biosciences Highlights Promising Long-Term Tralesinidase Data
Positive
Feb 5, 2026
On February 5, 2026, Spruce Biosciences reported long-term clinical data presented at the 22nd Annual WORLDSymposium showing that its investigational tralesinidase alfa enzyme replacement therapy (TA-ERT) produced rapid and durable reductions in h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.